Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A,

et al

.

Antibodies to human T-lymphotropic virus type-I in patients

 

with tropical spastic paraparesis. Lancet 1985; 2:407–410.

 

2. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita

 

KI,

 

 

et al.

Adult T-cell leukemia: antigen in an ATL cell line and

detection of antibodies to the antigen in human sera. Proc Natl

 

Acad Sci USA 1981; 78:6476–6480.

 

3. de The G, Kazanji M. An HTLV-I/II vaccine: from animal models

 

to clinical trials? J Acquir Immune Defic Syndr Hum Retrovirol

 

 

Figure1.

 

Map of HTLV-I Infection distribution in Golestan and Khorasan

provinces, Iran

 

235

Prevalence of HTLV-I Infection in Golestan, Iran Kalavi Kh et al

Iran J Basic Med Sci; Vol. 16, No. 3, Mar 2013

1996; 13:S191–198.

4. Pawson R, Mufti GJ, Pagliuca A. Management of adult T-cell leukaemia/

lymphoma. Br J Haematol 1998; 100:453–458.

5. Goncalves DU, Proietti FA, Ribas JG, Araujo MG, Pinheiro SR,

Guedes AC,

et al.

Epidemiology, treatment, and prevention of

human T-cell leukemia virus type 1-associated diseases. Clin Microbiol

 

Rev 2010; 23:577-589.

 

6. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL.

 

Global epidemiology of HTLV-I infection and associated diseases.

 

Oncogene 2005; 24:6058-6068.

 

7. Hino S, Doi H, Yoshikuni H, Sugiyama H, Yamabe T, Tsuji Y,

 

 

 

et al.

 

HTLV-I carrier mothers with high-titer antibody are at high risk

as a source of infection. Jpn J Cancer Res 1987; 78:1156–1158.

8. Wiktor SZ, Pate EJ, Rosenberg PS, Barnett M, Palmer P, Medeiros

D,

et al

. Mother-to-child transmission of human T-cell lymphotropic

virus type I associated with prolonged breastfeeding. J

 

Hum Virol 1997; 1:37–44.

 

9. Nomura K, Utsunomiya A, Furushou H, Tara M, Hazeki M, Tokunaga

 

M,

 

 

et al

. A family predisposition to adult T-cell leukemia. J

Clin Exp Hematop 2006; 46:67–71.

 

10. Tajima K, Sonoda S. Ethnoepidemiology, a new paradigm, for

 

studying cancer risk factors and prevention strategy. In: Tajima

 

K, Sonoda S, editors. Ethnoepidemiology of Cancer. Gann Monograph

 

No.44. Tokyo: Japanese Scientific Societies Press; 1996.p.3–

 

12.

 

11. Tavanai Sani A. Serologic prevalence of HTLV-I among blood donors

 

in Mashhad (North eastern of Iran). Arch Iran Med 2001;

 

4:25-26.

 

12. Farid R, Shirdel A. Phylogenetic of HTLV-I in Iranian born in

 

Mashhad. Arch Iran Med 1999; 2:24-25.

 

13. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F,

 

Bidkhori HR, Shamsian SKh, Ahmadi S,

 

 

et al.

High prevalence of

HTLV-I infection in Mashhad, Northeast Iran: A population-based

 

seroepidemiology survey. J Clin Virol 2011; 52:172– 176.

 

14. Moradi A, Mansurian AR, Ahmadi AR, Ghaemi E, Kalavi KH,

 

Marjani A,

 

 

et al

. Prevalence of HTLV-I among major thalassemic

patients in Gorgan (South East of Caspian Sea). J Appl Sci 2008;

 

8:391-393.

 

15. Giuliani M, Rezza G, Lepri AC, Di Carlo A, Maini A, Crescimbeni

 

E,

 

 

et al

. Risk factors for HTLV-I and II in individuals attending a

clinic for sexually transmitted diseases. Sex Transm Dis 2000;

 

27:87-92.

 

16. Wang HR, Yan YS, Zhang QW, Zheng J, Liu JM, Feng YY,

 

 

et al

. Seroepidemiological

study on the human T-cell leukemia virus type

 

I/II infection in the east coastal areas of Fujian province. Zhonghua

 

Liu Xing Bing Xue Za Zhi 2004; 25:428-430.

 

17. Biglione MM, Astarloa L, Salomon HE. High prevalence of HTLV-I

 

and HTLV-II among blood donors in Argentina: a South American

 

health concern. AIDS Res Hum Retroviruses 2005; 21:1-4.

 

18. Mozzi F, Rebulla P, Lillo F. HIV and HTLV infections in 1305 transfusion-

 

dependent thalassemics in Italy. AIDS 1992; 6:505-508.

 

19. Al-Mufti S, Voevodin A, Ahmed S, Al Hamdan S, Al-Basheer AA. Seroprevalence

 

of human T-Cell leukemia/lymphoma virus type I

 

and type II (HTLV-I/HTLV-II) infection among volunteer blood donors

 

in Kuwait. Med Princ Pract 1999; 1:45-50.

 

20. Pour Karim MR, Khamisi Pour GhR, Zandi K, Roustaei MH. Prevalence

 

of anti-HTLV-I & anti-HTLV-II antibodies in blood donors in

 

Bushehr province. Iran South Med J 2004; 2:164-161.

 

21. Moradi A, Yaghob Nezhad Z, Mohagheghi AH, Shahraki Sh, Borji

 

A, Firoozkohi MR,

 

 

et al.

Seroepidemiology of HTLV-I antibody in

the Thalassemic patients in Zahedan and Zaboul cities in 2001. J

 

Zanjan Univ Med Sci Health Services ? 2003; 43:47-43.

 

22. Goubau P, Carton H, Kazadi K, Muya KW, Desmyter J. HTLV seroepidemiology

 

in a central African population with high incidence

 

of tropical spastic paraparesis. Trans R Soc Trop Med Hyg 1990;

 

84:577-579.

 

23. Vrielink H, Reesink HW. HTLV-I/II prevalence in different geographic

 

locations. Transfus Med Rev 2004; 18:46-57.

 

24. Watanabe T. Current status of HTLV-I infection. Int J Hematol

 

2011; 94:430–434.

 

25. Sonoda Sh, Li HC, Tajima K. Ethnoepidemiology of HTLV-I related

 

diseases: Ethnic determinants of HTLV-I susceptibility and its

 

worldwide dispersal. Cancer Sci 2011; 102:297.

 

26. Murphy EL, Figueroa JP, Gibbs WN, Holding-Cobham M, Cranston

 

B, Malley K,

 

 

et al.

Human T-lymphotropic virus type I (HTLV-I)

seroprevalence in Jamaica. I. Demographic determinants. Am J

 

Epidemiol 1991; 133:1114–1124.

 

27. Biggar RJ, Johnson BK, Oster C, Sarin PS, Ocheng D, Tukei P,

 

 

 

et al.

 

Regional variation in prevalence of antibody against human Tlymphotropic

virus types I and III in Kenya, East Africa. Int J Cancer

1985; 35

:

763–767.

28. Wiktor SZ, Piot P, Mann JM, Nzilambi N, Francis H, Vercauteren

 

G,

 

 

et al.

Human T cell lymphotropic virus type I (HTLV-I) among

female prostitutes in Kinshasa. Zaire. J Infect Dis 1990; 161:1073–

 

1077.

 

29. Kondo T, Kono H, Miyamoto N, Yoshida R, Toki H, Matsumoto I

 

 

 

,

et al

 

 

 

. Age- and sex-specific cumulative rate and risk of ATLL for

HTLV-I carriers. Int J Cancer 1989; 43:1061–1064.

 

30. Dourado I, Alcantara LC, Barreto ML, da Gloria Teixeira M, Galvao-

 

Castro B. HTLV-I in the general population of Salvador, Brazil: a

 

city with African ethnic and sociodemographic characteristics. J

 

Acquir Immune Defic Syndr 2003; 34:527–531.

 

31. Armah HB, Narter-Olaga EG, Adjei AA, Asomaning K, Gyasi RK,

 

Tettey Y. Seroprevalence of human T-cell lymphotropic virus

 

type I among pregnant women in Accra, Ghana. J Med Microbiol

 

2006; 55:765–770.

 

32. Kazanji M, Gessain A. Human T-cell lymphotropic virus types I

 

and II (HTLVI/II) in French Guiana: clinical and molecular epidemiology.

 

Cad Saude Publica 2003; 19:1227–1240.

 

33. Plancoulaine S, Buigues RP, Murphy EL, van Beveren M, Pouliquen

 

JF, Joubert M,

 

 

et al.

Demographic and familial characteristics of

HTLV-I infection among an isolated, highly endemic population

 

of African origin in French Guiana. Int J Cancer 1998; 76:331–336.

 

34. Astier-Gin T, Portail JP, Londos-Gagliardi D, Moynet D, Blanchard

 

S, Dalibart R,

 

 

et al.

Neutralizing activity and antibody reactivity

toward immunogenic regions of the human T cell leukemia virus

 

type I surface glycoprotein in sera of infected patients with

 

different clinical states. J Infect Dis 1997; 175:716–719.

 

35. Londos-Gagliardi D, Armengaud MH, Freund F, Dalibart R, Moze

 

E, Huet S,

 

 

et al.

Antibodies directed against a variable and neutralizable

region of the HTLV-I envelope surface glycoprotein.

 

Leukemia 1997; 11:38–41.

 

36. Hadlock KG, Rowe J, Perkins S, Bradshaw P, Song GY, Cheng C

 

 

, et al

.

Neutralizing human monoclonal antibodies to conformational

 

epitopes of human T-cell lymphotropic virus type 1 and 2 gp46. J

 

Virol 1997; 71:5828–5840.

 

37. Hadlock KG, Rowe J, Foung SK. The humoral immune response

 

to human T-cell lymphotropic virus type 1 envelope glycoprotein

 

gp46 is directed primarily against conformational epitopes. J Virol

 

1999; 73:1205–1212.